[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100626625":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":19,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":19,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":19,"studyType":56,"phases":57,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":28,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"EBV-AST cell infusion","EXPERIMENTAL","EBV-AST (EBV-specific cell infusion) for the treatment of EBV-DNA viremia and prevention of PTLD in patients post-Allo-HSCT.",[13],"Biological: EBV-AST cell",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","EBV-AST cell",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Daihong Liu","CONTACT","+8613681171597","daihongrm@163.com",[27],{"facility":5,"status":28,"city":29,"state":19,"zip":19,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"RECRUITING","Beijing","China","CN",{"type":33,"coordinates":34},"Point",[35,36],116.39723,39.9075,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":41,"investigatorFullName":22,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Director, Department of Hematology","100626625","phase-1-ebv-ast-cell-therapy-for-ebv-related-diseases-after-stem-cell-transplantation-100626625",false,"NCT07438067","EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation","A Prospective Exploratory Study of EBV-AST Cell Injection for the Treatment of EBV-Related Diseases After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. The patient must be aged 18-75 years.\n2. ust have undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT).\n3. Must have EBV-DNA viremia post-transplant, with EBV-DNA \\> 1000 copies\u002FmL (on two consecutive tests or one test \\> 10,000 copies\u002FmL).\n4. Karnofsky Performance Score (KPS) of 70 or higher.\n5. Expected survival of at least 3 months.\n6. Sufficient organ function, including renal (serum creatinine ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL\u002Fmin), hepatic (AST, ALT, and total bilirubin ≤ 5 × ULN), and hematologic parameters (platelets ≥ 10 × 10\\^9\u002FL, neutrophils ≥ 1.0 × 10\\^9\u002FL).\n7. HLA-matching criteria must be met for the donor\u002Frecipient.\n\nExclusion Criteria:\n\n1. Active GVHD (Grade 2 or higher) or requiring \\>0.5 mg\u002Fkg\u002Fday corticosteroids for GVHD.\n2. History of CMV viremia or disease within the past week.\n3. PTLD (Post-Transplant Lymphoproliferative Disorder) diagnosed or suspected within 1 week before infusion.\n4. Severe active infections (excluding EBV and CMV).\n5. Serious allergic reactions or contraindications to the infusion.\n6. Previous immune therapy-related adverse events of Grade 3 or higher.\n7. History of HIV, HCV, or HBV infection with an active viral load.","ALL","18 Years","75 Years",{"count":54,"type":55},18,"ESTIMATED","INTERVENTIONAL",[58,59],"PHASE1","PHASE2","This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplantation (Allo-HSCT). The study aims to determine the maximum tolerated dose (MTD) or optimal biological dose (OBD) of EBV-AST cells and assess their safety, tolerability, and preliminary efficacy in treating EBV-DNA viremia. The study will involve a 3+3 dose escalation design to evaluate three different dosages of EBV-AST cell infusion. The study is expected to provide important insights into the clinical application of cell-based therapies for EBV infections.",[62,63],"EBV-DNA Viremia","Post-Transplant Lymphoproliferative Disorder",[65,66,9],"EBV-DNA viremia","Allogeneic Hematopoietic Stem Cell Transplantation","2026-02-26",{"date":69,"type":70},"2026-02-27","ACTUAL",{"date":72,"type":70},"2025-03-26",{"date":74,"type":55},"2028-03-26",{"name":22,"class":6},1]